Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress
Łukasz Bułdak
Orcid profile, Estera Skudrzyk
Orcid profile, Grzegorz Machnik
Orcid profile, Aleksandra Bołdys
Orcid profile, Rafał Jakub Bułdak
Orcid profile and Bogusław Okopień
Orcid profile 
Article Category: Original Article
Published Online: Feb 20, 2022
Page range: 16 - 23
Received: Jan 01, 2021
Accepted: Jul 16, 2021
DOI: https://doi.org/10.2478/ahem-2021-0037
Keywords
© 2022 Łukasz Bułdak et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Introduction
GLP-1 receptor agonists (e.g., exenatide) are novel drugs used in the treatment of diabetes. These drugs, working with other mechanisms of action, improve glycemic control by increasing secretion of insulin and improving survival of pancreatic islet beta cells. Alterations in the oxidative stress level or the expression of proteins associated with cholesterol uptake might be responsible for those findings. Currently, there are few
Materials and Method
An
Results
We showed that exenatide improves expression of catalase and reduces the amount of nitrite in cell cultures in a protein kinase A–dependent manner. Those results were accompanied by a drop in the expression of LDL receptors and PCSK9. Insulin secretion was modestly increased in the culture condition.
Conclusions
Our findings show potential protective mechanisms exerted by exenatide in human insulin-secreting pancreatic beta cell line (1.1E7), which may be exerted through increased antioxidant capacity and reduced accumulation of cholesterol.